GOTHENBURG, SE / ACCESSWIRE / September 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 13, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will give a presentation at the event Pareto Securities’ 15th Annual Healthcare Conference, in Stockholm on September 19, 2024.
Kristina Torfgård, CEO, will attend and present IRLAB at the event, hosted by Pareto Securities at Downtown Camper Scandic in Stockholm City.
“I am looking forward to meeting current and potential new investors to present our leading portfolio in Parkinson’s disease and the progress we are making. These are very exciting times for IRLAB,” said Kristina Torfgård, CEO.
More information about the event can be found on Pareto’s webpage:
https://paretosec.com/updates/events-and-conferences
For more information
Kristina Torfgård, CEO
Phone: +46 730 60 70 99
E-mail: kristina.torfgard@irlab.se
About IRLAB
IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson’s disease. The company originates from Nobel Laureate Prof Arvid Carlsson’s research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson’s disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB’s pipeline has been generated by the company’s proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .
Attachments
IRLAB participates in Pareto Securities’ 15th Annual Healthcare Conference
SOURCE: IRLAB Therapeutics
View the original press release on accesswire.com
— Recognition validates operator-led approach to solving administrative burden that costs U.S. healthcare system $31B…
SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a…
TAIPEI, Dec. 30, 2025 /PRNewswire/ -- TOMO YUME Group today announced that its subsidiary, Sparkling Sciences,…
A new frontier in fertility innovation begins as OTO introduces its advanced platform, delivering personalized…
HOUSTON, Dec. 30, 2025 /PRNewswire/ -- After a year marked by impactful patient outcomes, expanded…
Desert Oasis Healthcare leads community-wide effort to raise awareness and encourage vaccination amid ongoing mpox…